LCH was initially considered an immune-dysregulatory disorder rather than a neoplastic disorder, until somatic activation of gene mutations in the mitogen-activated protein kinase (MAPK) pathway were found in LCH patients, and reclassified LCH to be a myeloid neoplastic disorder (4, 15). Here, WNK2 is linked to Langerhans cell histiocytosis.